Review of the cardiovascular safety of dipeptidyl peptidase-4 inhibitors and the clinical relevance of the CAROLINA trial.

Published on Mar 15, 2019in BMC Cardiovascular Disorders2.298
· DOI :10.1186/S12872-019-1036-0
Marile L Santamarina4
Estimated H-index: 4
(Palm Beach Atlantic University),
Curt J. Carlson3
Estimated H-index: 3
(Palm Beach Atlantic University)
Sources
Abstract
Cardiovascular (CV) disease (CVD) is a well-recognized complication of type 2 diabetes mellitus (T2DM) and there is a clinical need for glucose-lowering therapies that do not further increase CV risk in this population. Although sulfonylureas (SUs) may be used as second-line therapy for patients requiring additional therapy after first-line metformin to improve glycemic control, their long-term effects on CV outcomes remain uncertain, and a wide range of alternative agents exist including dipeptidyl peptidase-4 (DPP-4) inhibitors. Literature searches in PubMed (2013–2018) were conducted with terms for DPP-4 inhibitors combined with CV terms, with preference given to cardiovascular outcomes trials (CVOTs). Reference lists from retrieved articles and diabetes guidelines were also considered. This narrative review discusses current evidence for the CV safety of these agents, describes the long-term CV effects of DPP-4 inhibitors, including effects on CV events, mortality, the risk for heart failure hospitalization, and highlights the need for further research into the CV effects of SU therapy. Although SUs remain a treatment option for T2DM, the long-term effects of these agents on CV outcomes are unclear, and further long-term studies are required. For DPP-4 inhibitors, uncertainties have been raised about their long-term effect on hospitalization for heart failure in light of the results of SAVOR-TIMI 53, although the findings of other DPP-4 inhibitor CVOTs in T2DM and data analyses have suggested these agents do not increase the occurrence of adverse CV outcomes. Based on recent CVOTs and guideline updates, the choice of add-on to metformin therapy for patients with T2DM and established CV disease should be a sodium-glucose co-transporter-2 inhibitor or a glucagon-like peptide-1 agonist with proven CV benefit. Additional treatment options for those individuals who require therapy intensification, as well as in patients with T2DM and without established CVD include DPP-4 inhibitors and SUs. Since few head-to-head trials have compared the effects of different oral glucose-lowering agents on CV outcomes in T2DM, with most CVOTs using placebo as a comparator, the CAROLINA trial will provide important information on the comparative CV safety of a commonly prescribed SU and a DPP-4 inhibitor.
📖 Papers frequently viewed together
References94
Newest
Abstract Background The cardiovascular safety profile of dapagliflozin, a selective inhibitor of sodium–glucose cotransporter 2 that promotes glucosuria in patients with type 2 diabetes, is undefined. Methods We randomly assigned patients with type 2 diabetes who had or were at risk for atherosclerotic cardiovascular disease to receive either dapagliflozin or placebo. The primary safety outcome was a composite of major adverse cardiovascular events (MACE), defined as cardiovascular death, myocar...
Source
#1Julio Rosenstock (UTSW: University of Texas Southwestern Medical Center)H-Index: 103
#2Vlado Perkovic (UNSW: University of New South Wales)H-Index: 94
Last. Darren K. McGuireH-Index: 95
view all 19 authors...
Importance Type 2 diabetes is associated with increased cardiovascular (CV) risk. Prior trials have demonstrated CV safety of 3 dipeptidyl peptidase 4 (DPP-4) inhibitors but have included limited numbers of patients with high CV risk and chronic kidney disease. Objective To evaluate the effect of linagliptin, a selective DPP-4 inhibitor, on CV outcomes and kidney outcomes in patients with type 2 diabetes at high risk of CV and kidney events. Design, Setting, and Participants Randomized, placebo-...
Source
#1Melanie J. Davies (University of Leicester)H-Index: 98
#2David A. D'Alessio (Duke University)H-Index: 87
Last. John B. Buse (UNC: University of North Carolina at Chapel Hill)H-Index: 121
view all 10 authors...
The American Diabetes Association and the European Association for the Study of Diabetes convened a panel to update the prior position statements, published in 2012 and 2015, on the management of type 2 diabetes in adults. A systematic evaluation of the literature since 2014 informed new recommendations. These include additional focus on lifestyle management and diabetes self-management education and support. For those with obesity, efforts targeting weight loss, including lifestyle, medication,...
Source
#1André Scheen (University of Liège)H-Index: 96
Abstract After failure of metformin monotherapy, another glucose-lowering agent should be added to improve glucose control. The clinician has several pharmacological choices, including the addition of a sulphonylurea (SU) or a dipeptidyl peptidase-4 inhibitor (DPP-4i). While the cardiovascular safety of SUs remains a matter of controversy, DPP-4is have proven their non-inferiority vs placebo in recent cardiovascular (CV) outcome trials. In the absence of a head-to-head CV outcome trial—the CAROL...
Source
#1Stephen D. Wiviott (Brigham and Women's Hospital)H-Index: 88
#2Itamar Raz (HUJI: Hebrew University of Jerusalem)H-Index: 69
Last. Marc S. Sabatine (Harvard University)H-Index: 125
view all 16 authors...
Abstract Background Dapagliflozin is a sodium-glucose co-transporter-2 (SGLT-2) inhibitor that reduces blood glucose in patients with type 2 diabetes mellitus (T2DM) by promoting glycosuria via inhibiting urinary glucose reabsorption. In addition to improving blood glucose control, treatment with dapagliflozin results in glucose-induced osmotic diuresis, weight loss, and blood pressure lowering. Previous trials of SGLT-2 inhibitors showed reductions in cardiovascular (CV) events, including CV de...
Source
#1Charles E. Leonard (UPenn: University of Pennsylvania)H-Index: 24
#2Colleen M. Brensinger (UPenn: University of Pennsylvania)H-Index: 71
Last. Sean Hennessy (UPenn: University of Pennsylvania)H-Index: 58
view all 10 authors...
OBJECTIVE To examine the association between individual antidiabetic sulfonylureas and outpatient-originating sudden cardiac arrest and ventricular arrhythmia (SCA/VA). RESEARCH DESIGN AND METHODS We conducted a retrospective cohort study using 1999–2010 U.S. Medicaid claims from five large states. Exposures were determined by incident use of glyburide, glimepiride, or glipizide. Glipizide served as the reference exposure, as its effects are believed to be highly pancreas specific. Outcomes were...
Source
#1Julio RosenstockH-Index: 103
#2Vlado Perkovic (The George Institute for Global Health)H-Index: 94
Last. Darren K. McGuire (UTSW: University of Texas Southwestern Medical Center)H-Index: 95
view all 17 authors...
Cardiovascular (CV) outcome trials in type 2 diabetes (T2D) have underrepresented patients with chronic kidney disease (CKD), leading to uncertainty regarding their kidney efficacy and safety. The CARMELINA® trial aims to evaluate the effects of linagliptin, a DPP-4 inhibitor, on both CV and kidney outcomes in a study population enriched for cardio-renal risk. CARMELINA® is a randomized, double-blind, placebo-controlled clinical trial conducted in 27 countries in T2D patients at high risk of CV ...
Source
#1Eberhard StandlH-Index: 41
#2Susanna R. Stevens (Duke University)H-Index: 48
Last. Rury R. Holman (University of Oxford)H-Index: 118
view all 12 authors...
OBJECTIVE Severe hypoglycemic events (SHEs) in type 2 diabetes are associated with subsequent cardiovascular (CV) event risk. We examined whether CV events were associated with subsequent SHE risk. RESEARCH DESIGN AND METHODS Time-dependent associations between SHEs and a composite CV end point (fatal/nonfatal myocardial infarction or stroke, hospitalization for unstable angina, hospitalization for heart failure [hHF]) were examined post hoc in 14,671 TECOS (Trial Evaluating Cardiovascular Outco...
Source
#1Milton Packer (Baylor University Medical Center)H-Index: 116
Rationale: Dipeptidyl peptidase-4 (DPP-4) inhibitors have increased the risk of heart failure events in both randomized clinical trials and observational studies, but the mechanisms that underlie their deleterious effect remain to be elucidated. Previous work has implicated a role of these drugs to promote cardiac fibrosis. Objective: This paper postulates that DPP-4 inhibitors increase the risk of heart failure events by activating the sympathetic nervous system to stimulate cardiomyocyte cell ...
Source
#1Alan J. Garber (BCM: Baylor College of Medicine)H-Index: 60
#2Martin J. Abrahamson (Harvard University)H-Index: 23
Last. Guillermo E. Umpierrez (Emory University)H-Index: 6
view all 20 authors...
Abbreviations: A1C = hemoglobin A1C; AACE = American Association of Clinical Endocrinologists; ACCORD = Action to Control Cardiovascular Risk in Diabetes; ACCORD BP = Action to Control Cardiovascular Risk in Diabetes Blood Pressure; ACEI = angiotensin-converting enzyme inhibitor; ADVANCE = Action in Diabetes and Vascular Disease: Preterax and Diamicron MR Controlled Evaluation; AGI = alpha-glucosidase inhibitor; apo B = apolipoprotein B; ASCVD = atherosclerotic cardiovascular disease; BAS = bile...
Source
Cited By9
Newest
#1Nikolaos P.E. Kadoglou (UCY: University of Cyprus)H-Index: 2
#2Emmanouil Korakas (Athens State University)H-Index: 1
Last. Vaia Lambadiari (Athens State University)H-Index: 15
view all 9 authors...
BACKGROUND Nesfatin-1, a novel adipokine and dipeptidyl peptidase-4 (DPP4), a mam malian serine protease, are potent factors of atherosclerosis. In the present cross-sectional study, we investigated whether the plasma nesfatin-1 and DPP4 is associated with the prevalence and severity of coronary artery disease (CAD) with and without diabetes mellitus (DM). METHODS We consecutively enrolled a total of 240 patients with significant CAD (previous revascularization or angiographically-proven coronar...
Source
#1Desye Gebrie (College of Health Sciences, Bahrain)H-Index: 2
#2Desalegn Getnet (College of Health Sciences, Bahrain)H-Index: 2
Last. Tsegahun Manyazewal (College of Health Sciences, Bahrain)H-Index: 11
view all 3 authors...
Diabetes is a serious threat to global health and among the top 10 causes of death, with nearly half a billion people living with it worldwide. Treating patients with diabetes tend to become more challenging due to the progressive nature of the disease. The role and benefits of combination therapies for the management of type 2 diabetes are well-documented, while the comparative safety and efficacy among the different combination options have not been elucidated. We aimed to systematically synth...
Source
#1Lars Bernfort (Linköping University)H-Index: 16
#2Magnus Husberg (Linköping University)H-Index: 15
Last. Lars-Åke Levin (Linköping University)H-Index: 27
view all 7 authors...
Cardiovascular disease (CVD) affects approximately 30% of patients with diabetes mellitus type 2 (T2D) and leads to increased morbidity, decreased survival and increased healthcare utilization. The aim of this study was to estimate the impact of treating these patients with the sodium–glucose cotransporter 2 (SGLT2) inhibitor empagliflozin on survival and healthcare utilization. Actual survival and healthcare utilization data from a 5-year retrospective cohort study on patients with T2D and CVD ...
Source
#1Anca Pantea Stoian (UMFCD: Carol Davila University of Medicine and Pharmacy)H-Index: 14
#2Alexandros Sachinidis (A.U.Th.: Aristotle University of Thessaloniki)H-Index: 6
Last. Ali A. Rizvi (Emory University)H-Index: 24
view all 6 authors...
INTRODUCTION The dipeptidyl peptidase-4 inhibitors (DPP-4is), which belong to the class of incretin-based medications, are recommended as second or third-line therapies in guidelines for the management of type 2 diabetes mellitus. They have a favorable drug tolerability and safety profile compared to other glucose-lowering agents. OBJECTIVE This review discusses data concerning the use of DPP-4is and their cardiovascular profile, and gives an updated comparison with the other oral glucose-loweri...
Source
view all 3 authors...
Source
#1Lars Bernfort (Linköping University)H-Index: 16
#2Magnus Husberg (Linköping University)H-Index: 15
Last. Lars-Åke Levin (Linköping University)H-Index: 27
view all 7 authors...
INTRODUCTION Type 2 diabetes (T2D) is a complex chronic disease with an increasing prevalence worldwide. It is commonly associated with complications, such as cardiovascular disease (CVD). Patients with both T2D and established CVD are exposed to increased risk of further cardiovascular events, which means increased healthcare costs and impairments to quality of life and survival. To determine the added burden of CVD for T2D patients, we have analyzed the consumption and costs of healthcare and ...
Source
#1Desye Gebrie (College of Health Sciences, Bahrain)H-Index: 2
#2Desalegn Getnet (College of Health Sciences, Bahrain)H-Index: 2
Last. Tsegahun Manyazewal (College of Health Sciences, Bahrain)H-Index: 11
view all 3 authors...
Background: Diabetes mellitus is a serious threat to global health and among the top 10 causes of death, with nearly half a billion people living with it worldwide. Treating patients with diabetes tend to become more challenging due to the nature of the disease. The role and benefits of combination therapies for the management of type 2 diabetes are well-documented, while the comparative safety and efficacy among the different combination options have not been elucidated. We aimed to systematica...
Source
#1Guntram Schernthaner (Medical University of Vienna)H-Index: 8
#2Christoph WannerH-Index: 109
Last. István Wittmann (PTE: University of Pécs)H-Index: 23
view all 14 authors...
Abstract Dipeptidyl peptidase-4 (DPP-4) inhibitors are a class of glucose-lowering agent for type 2 diabetes (T2D) that are commonly used in clinical practice. With the recent disclosure of data from the CARMELINA cardiovascular outcomes trial (CVOT), which investigated linagliptin, CV and renal outcomes data are now available for four agents in the DPP-4 inhibitor class that are approved in most markets. To consider how the CARMELINA study may be interpreted, and the relevance for our clinical ...
Source
In the 1990s it was discovered that the enzyme dipeptidyl peptidase-4 (DPP-4) inactivates the incretin hormones glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). DPP-4 inhibition results in raised levels of the two incretin hormones which in turn result in lowering of circulating glucose through stimulation of insulin secretion and inhibition of glucagon secretion. Since then, several small orally available molecules have been developed with DPP-4 inhibitory...
Source
This website uses cookies.
We use cookies to improve your online experience. By continuing to use our website we assume you agree to the placement of these cookies.
To learn more, you can find in our Privacy Policy.